Health Observer Falkland Islands: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Observer Falkland Islands.

Press releases published on September 9, 2026

Sep. 9, 2026

Fractyl Health to Participate in Upcoming September Investor Conferences

Indeterminate GlobeNewswire

Sep. 9, 2026

Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis

Indeterminate GlobeNewswire

Sep. 9, 2026

Onco360® Has Been Selected as Part of an Ultra-Narrow Specialty Pharmacy Network for MIMRYLO™ (rusfertide)

Indeterminate GlobeNewswire

Sep. 9, 2026

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

Indeterminate GlobeNewswire

Sep. 9, 2026

Solstice Oncology Launches with $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy

Indeterminate GlobeNewswire

Sep. 9, 2026

Beeline Medicines Announces Positive Topline Results from Global Phase 2 Study of Afimetoran in Systemic Lupus Erythematosus

Indeterminate GlobeNewswire

Sep. 9, 2026

Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment

Indeterminate GlobeNewswire

Sep. 9, 2026

Broncos Country, This One’s for You: Breckenridge Distillery Kicks Off Another Season with the Denver Broncos and a Limited-Edition Whiskey Collection Honoring “The Drive”

Indeterminate GlobeNewswire

Sep. 9, 2026

ABBYY Study Finds Business Leaders Disagree on Who Has Ultimate Responsibility When AI Goes Wrong

Indeterminate GlobeNewswire

Sep. 9, 2026

Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society

Indeterminate GlobeNewswire

Sep. 9, 2026

Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib

Indeterminate GlobeNewswire

Sep. 9, 2026

Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

Indeterminate GlobeNewswire

Sep. 9, 2026

MapLight Therapeutics to Participate in Upcoming Investor Conference

Indeterminate GlobeNewswire

Sep. 9, 2026

Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

Indeterminate GlobeNewswire

Sep. 9, 2026

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Indeterminate GlobeNewswire

Sep. 9, 2026

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

Indeterminate GlobeNewswire

Sep. 9, 2026

LifeStance Health Group Announces Launch of Secondary Public Offering

Indeterminate GlobeNewswire

Sep. 9, 2026

OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026

Indeterminate GlobeNewswire

Sep. 9, 2026

Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation

Indeterminate GlobeNewswire

Sep. 9, 2026

Invisible Balance Disorders Affect Millions

Indeterminate GlobeNewswire